Search
for
Sort by
Research 751–780 of 1000+
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Treatment of Scleroderma-Related Microstomia Using Hyaluronic Acid: An Interventional Study
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Biomedical engineering approaches for the delivery of JAGGED1 as a potential tissue regenerative therapy
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications
- Perspective Chapter: Repurposing Natural Products to Target COVID-19 – Molecular Targets and New Avenues for Drug Discovery
- Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
- Research Progress on the Immunomodulatory Effects by Dang Gui (Radix Angelica sinensis) and Its Active Chemical Components
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Treating Psoriasis: What Is New About Fumaric Acid Esters?
- Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- New therapies for alopecia areata
- Isotretinoin and Hair Loss: A Clinical Perspective and Literature Review